TrialCancer chemotherapy and pharmacology2025

Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.

Sherwin K B Sy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.